Minimal residual disease prognostic value for relapse-free survival of children with acute lymphoblastic leukemia treating according to ALL-MB-2002 protocol (monofactorial and multifactirial analysis)

N. N. Savva; Савва Н. Н.; O. V. Kras'ko; Красько О. В.; M. V. Belevtcev; Белевцев М. В.; V. P. Savitckiy; Савицкий В. П.; N. V. Migal; Мигаль Н. В.; O. V. Aleinikova; Алейникова О. В.

doi:10.17650/1818-8346-2009-0-2-17-21

Minimal residual disease prognostic value for relapse-free survival of children with acute lymphoblastic leukemia treating according to ALL-MB-2002 protocol (monofactorial and multifactirial analysis)

Authors: Savva N.N.¹, Kras'ko O.V.¹, Belevtcev M.V.¹, Savitckiy V.P.¹, Migal N.V.¹, Aleinikova O.V.¹
Affiliations:
1. Republic Centre for Paediatric Oncology and Haematology
Issue: No 2 (2009)
Pages: 17-21
Section: HEMATOLOGIC MALIGNANCIES: TREATMENT, SUPPORTIVE CARE
Published: 27.05.2009
URL: https://oncohematology.abvpress.ru/ongm/article/view/735
DOI: https://doi.org/10.17650/1818-8346-2009-0-2-17-21
ID: 735

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

220 children with acute lymphoblastic leukemia (ALL) treated according to ALL-MB-2002 protocol are included in the study. Minimal residual disease (MRD) estimated in bone marrow by three-color flow cytometry on day 15 (n=99), day 36 (n=107) and before the maintenance therapy (n=60). Day 36 positive MRD level (≥0.01%) as one of unfavorable factors statistically significant worsening of relapse-free survival was revealed (log-rank test; р<0.05). In multifactorial analysis (Cox regression) it is revealed that positive MRD level on day 36 of treatment is the strongest and independent prognostic factor influencing relapse probability (hazard ratio 6.6; p=0.031). Necessity of additional patients' stratification introduction according to MRD level after induction is proved.